Research programme: MCR4 agonist therapeutic - Palatin Technologies
Alternative Names: MCR4 agonist therapeutic - Palatin Technologies; Melanocortin 4 receptor agonist - Palatin TechnologiesLatest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Palatin Technologies
- Class Peptides; Small molecules
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 25 Jul 2024 Preclinical trials in Obesity in USA (unspecified route), prior to July 2024 (Palatin Technologies pipeline, July 2024)